Literature DB >> 10791987

Prodrug-activating systems in suicide gene therapy.

C J Springer1, I Niculescu-Duvaz.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10791987      PMCID： PMC315452          DOI： 10.1172/JCI10001

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  28 in total

Review 1.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

Authors:  T Hermiston
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Immunomodulation of cancer: potential use of selectively replicating agents.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

Authors:  J A Bridgewater; C J Springer; R J Knox; N P Minton; N P Michael; M K Collins
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

4.  Self-immolative anthracycline prodrugs for suicide gene therapy.

Authors:  I Niculescu-Duvaz; D Niculescu-Duvaz; F Friedlos; R Spooner; J Martin; R Marais; C J Springer
Journal:  J Med Chem       Date:  1999-07-01       Impact factor: 7.446

5.  Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.

Authors:  M E Black; T G Newcomb; H M Wilson; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 6.  Improving enzymes for cancer gene therapy.

Authors:  L P Encell; D M Landis; L A Loeb
Journal:  Nat Biotechnol       Date:  1999-02       Impact factor: 54.908

7.  Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.

Authors:  C C Heise; A Williams; J Olesch; D H Kirn
Journal:  Cancer Gene Ther       Date:  1999 Nov-Dec       Impact factor: 5.987

8.  The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication.

Authors:  R L Touraine; H Ishii-Morita; W J Ramsey; R M Blaese
Journal:  Gene Ther       Date:  1998-12       Impact factor: 5.250

9.  In vivo analysis of the 'bystander effect': a cytokine cascade.

Authors:  R Ramesh; A J Marrogi; A Munshi; C N Abboud; S M Freeman
Journal:  Exp Hematol       Date:  1996-06       Impact factor: 3.084

10.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

Authors:  B E Huber; E A Austin; C A Richards; S T Davis; S S Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205
View more
  48 in total

Review 1.  Regulatable systems: applications in gene therapy and replicating viruses.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

Authors:  T Hermiston
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 3.  Immunomodulation of cancer: potential use of selectively replicating agents.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

4.  Using intron splicing trick for preferential gene expression in transduced cells: an approach for suicide gene therapy.

Authors:  F Pourzadegan; L Shariati; R Taghizadeh; H Khanahmad; Z Mohammadi; M A Tabatabaiefar
Journal:  Cancer Gene Ther       Date:  2015-12-18       Impact factor: 5.987

5.  Understanding apoptotic signaling pathways in cytosine deaminase-uracil phosphoribosyl transferase-mediated suicide gene therapy in vitro.

Authors:  P Gopinath; Siddhartha Sankar Ghosh
Journal:  Mol Cell Biochem       Date:  2008-12-14       Impact factor: 3.396

6.  Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor.

Authors:  Mai Johnson; Breanne D W Karanikolas; Saul J Priceman; Russell Powell; Margaret E Black; Hsiao-Ming Wu; Johannes Czernin; Sung-Cheng Huang; Lily Wu
Journal:  J Nucl Med       Date:  2009-04-16       Impact factor: 10.057

7.  A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.

Authors:  Zahra Mohammadi; Laleh Shariati; Hossein Khanahmad; Mahsa Kolahdouz; Fariborz Kianpoor; Jahan Afrooz Ghanbari; Zahra Hejazi; Mansoor Salehi; Parvaneh Nikpour; Mohammad Amin Tabatabaiefar
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

Review 8.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

9.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

10.  Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT.

Authors:  Sepideh Afshar; Tove Olafsen; Anna M Wu; Sherie L Morrison
Journal:  J Exp Clin Cancer Res       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.